Search the Newsreel

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Holding AG has published notifications regarding transactions by persons discharging managerial responsibilities. These notifications relate to the vesting and settlement of Restricted Stock Units (RSUs) previously granted to company directors. The listed individuals include Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, …

Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. has reduced its price target for Oculis (NASDAQ:OCS) to $20.00 from $23.00, while maintaining an "overweight" rating. Despite this reduction and similar cuts by other firms, Oculis still holds a consensus "Moderate Buy" rating with an average price target of …

Crocs Jumps 26.9% in Three Months as Growth Signals Keep Strengthening

Shares of Crocs, Inc. CROX have gained 26.9% in the past three months, putting the focus on whether improving brand trends can support further progress. The rally has coincided with firmer direct-to-consumer demand, international expansion and a broader product mix. The operating picture is …

Is CROX a Buy Now as Low Valuation Meets HEYDUDE and Tariff Risks?

Crocs, Inc. CROX presents investors with a clear valuation-versus-execution trade-off. The stock trades at a sizable discount to several market benchmarks, while improving Crocs Brand trends and cash generation offer support. HEYDUDE weakness and tariff-related margin pressure, however, keep the near-term investment case from …

Crocs Raises 2026 Outlook as DTC Growth Helps Offset Tariff Pressure

Crocs, Inc. CROX raised its 2026 outlook after a stronger second quarter, putting execution at the center of the investment case. Direct-to-consumer growth, international gains and new products are supporting the Crocs Brand. Crocs, Inc. Price, Consensus and EPS SurpriseCrocs, Inc. Price, Consensus and …

Stifel reiterates Buy rating on Oculis stock, $40 target

Stifel has reiterated a Buy rating and a $40 price target for Oculis Holding AG (NASDAQ:OCS), based on discussions about its lead asset, privosegtor. Despite a recent stock drop and an "overvalued" assessment by InvestingPro, analysts maintain a strong buy consensus. Oculis is shifting …

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

Shares of Oculis Holding AG (OCS) have recently gained 1.7%, and Wall Street analysts project a potential rally of 187.83%, with a mean estimate of $36.9. Despite the inherent skepticism surrounding analyst price targets, a strong agreement among analysts on OCS's earnings potential and …

Does Weaker EPS Guidance And AI Pivot Change The Bull Case For Amdocs (DOX)?

CALLEN Helps Bring Crocs’ New Mascot to Life Through New Micro-Series

Crocs has introduced its first official mascot, Niles, a 6’0″ crocodile, to celebrate its 25th anniversary. Independent creative agency CALLEN partnered with Crocs to develop a social-first content platform, including a micro-series filmed in Crocs’ offices, to establish Niles' personality and engage audiences. The …

Crocs debuts social media mascot ‘Niles’

Crocs Inc. has introduced "Niles," a new social media mascot based on its digital crocodile logo, standing six feet tall. Niles was revealed after a series of "Easter eggs" and a 24-hour countdown, with Crocs planning to deploy him through social-first content, including episodic …

Crocs Introduces Niles: New Mascot Launches a Bold New Era of Character-Driven Storytelling

Crocs has introduced Niles, its official mascot, marking a new era of character-driven storytelling for the brand. Niles, a 6'0" crocodile, has been a subtle part of the Crocs brand since its inception in 2002, and his launch includes a social-first micro-series showcasing his …

Crocs inks AI tech deal

Crocs, Inc. has entered a 10-year strategic partnership with Infosys, an AI-centric business consulting and technology firm. This collaboration aims to modernize Crocs' business and IT systems to reduce costs, streamline operations, and support future growth through an AI-first approach. The footwear company will …

Amdocs (DOX) Q3 2026 Earnings Call Transcript

What Crocs (CROX)'s Profit Return And Upgraded 2026 Guidance Means For Shareholders

Crocs, Inc. reported a significant return to profitability in Q2 2026 with sales of US$1,179.47 million and net income of US$204.89 million, leading to an upgraded full-year 2026 revenue and earnings guidance. The company now expects revenue growth of 1% to 2% and GAAP …

Amdocs at Oppenheimer conference: ai push targets telecom reinvention

Amdocs (DOX) unveiled a new strategy at the Oppenheimer 29th Annual Technology, Internet & Communications Conference, focusing on AI, cloud acceleration, edge computing, and telecom connectivity. The company aims to reinvent the telecom industry by leveraging AI for operational efficiency and creating new revenue …

HC Wainwright Has Negative Estimate for Oculis Q3 Earnings

HC Wainwright has lowered its Q3 2026 EPS estimate for Oculis (NASDAQ: OCS) to a loss of $0.48 per share, maintaining a "Buy" rating and a $26 price target. Oculis previously reported a Q2 loss of $0.20 per share with $0.38 million in revenue …

Amdocs is one of the 5% of companies turning AI into real P&L returns. Here's how.

Amdocs, a telecoms services giant, has successfully leveraged AI to achieve significant P&L returns, standing out from the 95% of companies that see no gain from AI investments. By focusing on skill-based organization and internal mobility, Amdocs increased internal mobility to 40% and reduced …

Crocs Inc (CROX) News, Articles, Events & Latest Updates

This page provides a collection of recent news and articles related to Crocs Inc (CROX), including its introduction of a new mascot, Niles, and its Q2 2026 earnings call transcript. Other news covers analysts' takes on the company's performance, its tax strategy, and its …

Crocs Inc (CROX) Shares Fall 4.7% -- What GF Score of 80 Tells Investors

Crocs Inc. (CROX) shares recently fell 4.7% and are down 6.7% over the past week, with the stock currently trading at $131.71. GuruFocus assesses CROX as overvalued, with its current price 7.9% above the GF Value™ of $122.03 and a P/E ratio higher than …

Insider Selling: Crocs (NASDAQ:CROX) CEO Sells $2,649,291.52 in Stock

Crocs CEO Andrew Rees sold 19,072 shares of the company's stock for approximately $2.65 million on August 10th, reducing his direct ownership by 2.6%. The sale occurred near the stock's 52-week high, with shares trading at $133.01 after a $5.17 fall. Crocs, which has …

Crocs (NASDAQ:CROX) CEO Sells $1,505,441.28 in Stock

Crocs CEO Andrew Rees sold 10,928 shares of CROX stock for over $1.5 million at an average price of $137.76, reducing his ownership by 1.47%. This sale follows other recent transactions by Rees. The company recently beat earnings estimates, and analysts maintain a "Moderate …

DOX Q2 Deep Dive: Agentic Strategy and aOS Platform Drive Customer Engagement

DOX Q2 Deep Dive: Agentic Strategy and aOS Platform Drive Customer Engagement Telecom software provider Amdocs (NASDAQ:DOX) met Wall Street's revenue expectations in Q2 CY2026, with sales up 2.7% year on year to $1.17 billion. Its non-GAAP profit of $1.84 per share was in …

Crocs, Inc. (CROX) CEO-linked trust sells 30,000 shares in August trades

A trust associated with Crocs, Inc. CEO Andrew Rees sold a total of 30,000 shares of common stock on August 7 and 10, 2026, in open-market transactions. The shares were sold at weighted-average prices ranging between $136.78 and $140.05 per share, resulting in a …

Amdocs (DOX) Following Mixed Results And Lowered Outlook Still Looks Undervalued

Amdocs (DOX) remains undervalued despite mixed earnings and lowered profit guidance, as its fair value of $82.03 is significantly above its current trading price of $58.59. The company exhibits strong financial characteristics with recurring revenue streams, a high renewal rate for managed services, and …

Oculis rebuilds pipeline with Privosegtor buy from Accure

Oculis Holding AG has acquired all worldwide development and commercial rights to Privosegtor and ACT-02 from Accure Therapeutics for $3.8 million cash and up to 2,050,000 Oculis shares. This acquisition follows Oculis's Phase III OCS-01 failure and aims to consolidate its pipeline around these …

Crocs Insider Sold Shares Worth $4,154,785, According to a Recent SEC Filing

An insider at Crocs, Inc. recently sold shares totaling $4,154,785, as reported in a new SEC filing. This transaction occurred on the same day other news emerged regarding the company, including an adjustment to Crocs' price target by UBS and various earnings announcements. Crocs …

Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results

Oculis Holding AG has announced an asset purchase agreement with Accure Therapeutics to acquire global rights to Privosegtor, a neuroprotective drug candidate, for an upfront payment of $3.8 million and up to 2,050,000 Oculis ordinary shares. This strategic move follows the failure of Oculis's …

Crocs (CROX) Returned To Profit And Raised Guidance, Is The Upside Already Priced In?

Weekly Recap: Q2 adjusted OIBDA growth and Amdocs 10-year AI IT deal

Liberty Latin America Ltd. (LILA) reported Q2 revenue of approximately $1.1 billion, with adjusted OIBDA increasing by 5% and free cash flow reaching $58 million. The company also announced a 10-year IT deal with Amdocs for its Agentic OS, aiming to integrate AI-driven operations, …

Crocs stock rating held at Neutral by BTIG after model shift

BTIG has reiterated a Neutral rating on Crocs (NASDAQ:CROX) after discussions regarding its Q2 report and a model shift from direct-to-consumer to wholesale for a key online marketplace. This shift is expected to pressure total sales due to lower recognized revenues from direct-to-consumer channels …

Crocs insider plans sale of 19,072 common shares | CROX SEC Filing - Form 144

A Crocs (CROX) insider has filed a Form 144 indicating an intention to sell 19,072 shares of common stock through Morgan Stanley Smith Barney LLC on or after August 10, 2026. The shares are related to previously granted Performance Stock Units and Restricted Stock …

Amdocs (DOX) International Revenue Performance Explored

Have you evaluated the performance of Amdocs' (DOX) international operations during the quarter that concluded in June 2026? Considering the extensive worldwide presence of this provider of computer systems integration, analyzing the patterns in international revenues is crucial for understanding its financial resilience and …

Oculis Holding (OCS) inks $3.8M cash-plus-shares deal for Privosegtor rights

Oculis Holding AG has agreed to acquire full development and commercial rights to Privosegtor (ACT-01) and preclinical candidate ACT-02 from Accure Therapeutics for an upfront cash payment of $3.8 million and up to 2,050,000 Oculis ordinary shares. This deal terminates a prior licensing agreement, …